Trial Profile
Pivotal single dose 2-way bioequivalence study of ELI 202 under fasting and fed conditions in volunteers.
Status:
Recruiting
Phase of Trial:
Phase I
Latest Information Update: 27 May 2014
Price :
$35
*
At a glance
- Drugs ELI 202 (Primary)
- Indications Opioid-related disorders; Pain
- Focus Pharmacokinetics; Registrational
- Sponsors Elite Pharmaceuticals
- 27 May 2014 New trial record